Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy
Triple-negative breast cancer (TNBC) is among the aggressive subtype of breast cancer with a distinct lack of viable treatment strategies and poor clinical outcomes. Anti-PD-1 chemoimmunotherapy (CIT), which leverages the vast array of immunomodulatory effects induced by chemotherapeutic agents to p...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2527303 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849427836412100608 |
|---|---|
| author | Mohammed O. Gbadamosi Elizabeth Molchan Mariana S. Makarem Kennedy L. Coleman Alyssa C. Ohaegbulam Kathleen H. Streeks |
| author_facet | Mohammed O. Gbadamosi Elizabeth Molchan Mariana S. Makarem Kennedy L. Coleman Alyssa C. Ohaegbulam Kathleen H. Streeks |
| author_sort | Mohammed O. Gbadamosi |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is among the aggressive subtype of breast cancer with a distinct lack of viable treatment strategies and poor clinical outcomes. Anti-PD-1 chemoimmunotherapy (CIT), which leverages the vast array of immunomodulatory effects induced by chemotherapeutic agents to potentiate anti-PD-1 blockade, has emerged as a promising standard-of-care treatment option. However, the clinical benefit from anti-PD-1 CIT has been limited and heterogeneous in advanced TNBC. One of the major reasons for these limitations is the lack of understanding regarding the immunomodulatory properties of chemotherapeutics with respect to individual patients. In this review, we discuss the immunomodulatory properties of first-line chemotherapeutic agents in TNBC and the potential benefits that optimizing chemoimmunomodulation offers toward maximizing CIT efficacy in TNBC. |
| format | Article |
| id | doaj-art-41f8e02a83ff4d2e81b1ffb1bec24222 |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-41f8e02a83ff4d2e81b1ffb1bec242222025-08-20T03:28:54ZengTaylor & Francis GroupOncoImmunology2162-402X2025-12-0114110.1080/2162402X.2025.2527303Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacyMohammed O. Gbadamosi0Elizabeth Molchan1Mariana S. Makarem2Kennedy L. Coleman3Alyssa C. Ohaegbulam4Kathleen H. Streeks5Department of Pharmacotherapy and Translational Research, College of Pharmacy, Gainesville, FL, USADepartment of Pharmacotherapy and Translational Research, College of Pharmacy, Gainesville, FL, USADepartment of Pharmacotherapy and Translational Research, College of Pharmacy, Gainesville, FL, USADepartment of Pharmacotherapy and Translational Research, College of Pharmacy, Gainesville, FL, USADepartment of Pharmacotherapy and Translational Research, College of Pharmacy, Gainesville, FL, USADepartment of Pharmacotherapy and Translational Research, College of Pharmacy, Gainesville, FL, USATriple-negative breast cancer (TNBC) is among the aggressive subtype of breast cancer with a distinct lack of viable treatment strategies and poor clinical outcomes. Anti-PD-1 chemoimmunotherapy (CIT), which leverages the vast array of immunomodulatory effects induced by chemotherapeutic agents to potentiate anti-PD-1 blockade, has emerged as a promising standard-of-care treatment option. However, the clinical benefit from anti-PD-1 CIT has been limited and heterogeneous in advanced TNBC. One of the major reasons for these limitations is the lack of understanding regarding the immunomodulatory properties of chemotherapeutics with respect to individual patients. In this review, we discuss the immunomodulatory properties of first-line chemotherapeutic agents in TNBC and the potential benefits that optimizing chemoimmunomodulation offers toward maximizing CIT efficacy in TNBC.https://www.tandfonline.com/doi/10.1080/2162402X.2025.2527303Chemoimmunomodulationchemotherapyimmune-checkpoint inhibitorsimmunotherapytriple-negative breast cancer |
| spellingShingle | Mohammed O. Gbadamosi Elizabeth Molchan Mariana S. Makarem Kennedy L. Coleman Alyssa C. Ohaegbulam Kathleen H. Streeks Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy OncoImmunology Chemoimmunomodulation chemotherapy immune-checkpoint inhibitors immunotherapy triple-negative breast cancer |
| title | Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy |
| title_full | Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy |
| title_fullStr | Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy |
| title_full_unstemmed | Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy |
| title_short | Chemoimmunomodulation in triple negative breast cancer: a key to maximizing anti-PD-1 chemoimmunotherapeutic efficacy |
| title_sort | chemoimmunomodulation in triple negative breast cancer a key to maximizing anti pd 1 chemoimmunotherapeutic efficacy |
| topic | Chemoimmunomodulation chemotherapy immune-checkpoint inhibitors immunotherapy triple-negative breast cancer |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2527303 |
| work_keys_str_mv | AT mohammedogbadamosi chemoimmunomodulationintriplenegativebreastcancerakeytomaximizingantipd1chemoimmunotherapeuticefficacy AT elizabethmolchan chemoimmunomodulationintriplenegativebreastcancerakeytomaximizingantipd1chemoimmunotherapeuticefficacy AT marianasmakarem chemoimmunomodulationintriplenegativebreastcancerakeytomaximizingantipd1chemoimmunotherapeuticefficacy AT kennedylcoleman chemoimmunomodulationintriplenegativebreastcancerakeytomaximizingantipd1chemoimmunotherapeuticefficacy AT alyssacohaegbulam chemoimmunomodulationintriplenegativebreastcancerakeytomaximizingantipd1chemoimmunotherapeuticefficacy AT kathleenhstreeks chemoimmunomodulationintriplenegativebreastcancerakeytomaximizingantipd1chemoimmunotherapeuticefficacy |